Evidence map›Paper›PMID 40630326›Full record

ArticleKidney international reports2025

One-Year Outcomes After Belatacept Conversion in Adolescent Kidney Transplant Recipients.

Charlotte Duneton, Roshan George, Rochelle Liverman, Anne-Laure Sellier-Leclerc, Beatrice Beauval, Véronique Baudouin, Elodie Cheyssac, Barry Warshaw, Julien Hogan, Rouba Garro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Charlotte DunetonPediatric Nephrology, Dialysis, and Transplantation Department, Robert Debré University Hospital, APHP, Paris Cité University, Paris, France.
Roshan GeorgePediatric Nephrology Department, Emory School of Medicine and Children's Healthcare of Atlanta, Georgia, USA.
Rochelle LivermanPediatric Nephrology Department, Emory School of Medicine and Children's Healthcare of Atlanta, Georgia, USA.
Anne-Laure Sellier-LeclercPediatric Nephrology Department, Mother-Child University Hospital, Lyon, France.
Beatrice BeauvalPediatric Nephrology Department, Félix Guyon University Hospital, La Réunion, France.
Véronique BaudouinPediatric Nephrology, Dialysis, and Transplantation Department, Robert Debré University Hospital, APHP, Paris Cité University, Paris, France.
Elodie CheyssacPediatric Nephrology, Dialysis, and Transplantation Department, Robert Debré University Hospital, APHP, Paris Cité University, Paris, France.
Barry WarshawPediatric Nephrology Department, Emory School of Medicine and Children's Healthcare of Atlanta, Georgia, USA.
Julien HoganPediatric Nephrology, Dialysis, and Transplantation Department, Robert Debré University Hospital, APHP, Paris Cité University, Paris, France.
Rouba GarroPediatric Nephrology Department, Emory School of Medicine and Children's Healthcare of Atlanta, Georgia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Belatacept (CTLA4-Ig) has shown efficacy in adult kidney transplantation (KT) recipients (improved graft and patient survival and reduced Methods: Indications included long-term CNI avoidance because of toxicity (e.g., histological changes, posttransplant diabetes, and tremors), suboptimal creatinine, or to improve adherence. One-year outcomes were compared with a propensity-matched cohort of adolescents remaining on CNIs. Results: The median age was 17 years. Rejection occurred in 11 of 45 patients (24%) at a median of 10 months postconversion (7 T-cell-mediated rejections, 3 antibody-mediated rejections, 1 mixed). Belatacept was discontinued in 3 of 11 patients whereas CNIs were added in 2 of 11. Rejection and Conclusion: Although rejection rates in pediatric patients on belatacept seemed higher than in adult cohorts, they were not significantly different from adolescent patients on CNI, underscoring the challenges related to nonadherence in this population. Tailored immunosuppression strategies, including belatacept, may offer benefits for selected adolescents, but further studies are necessary to define optimal patient selection.

Indexed as

belataceptcostimulation blockadekidney transplantationoutcomespediatrics

Identifiers

PMID40630326
PMCPMC12232964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.